NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03425643,"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)",https://clinicaltrials.gov/study/NCT03425643,,ACTIVE_NOT_RECRUITING,"This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).",YES,Non-small Cell Lung Cancer,BIOLOGICAL: Pembrolizumab|DRUG: Placebo|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Pemetrexed,"Event Free Survival (EFS), EFS is defined as the time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause. EFS determined either by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The EFS for all participants is presented (through database cut-off date of 10-Jul-2023)., Up to approximately 5 years|Overall Survival (OS), OS is defined as the time from randomization until death from any cause. The OS for all participants is presented (through database cut-off date of 10-Jul-2023)., Up to approximately 5 years","Major Pathological Response (mPR) Rate, mPR rate is defined as the percentage of participants having â‰¤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy. The mPR rates as assessed by blinded independent pathologist are presented., Up to approximately 8 weeks following completion of neoadjuvant treatment (up to Study Week 20)|Pathological Complete Response (pCR) Rate, pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected lung specimens and lymph nodes following completion of neoadjuvant therapy. The pCR rates as assessed by blinded independent pathologist are presented., Up to approximately 8 weeks following completion of neoadjuvant treatment (up to Study Week 20)|Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score, Change from baseline in GHS/QoL score using the EORTC QLQ-C30 will be determined. The EORTC QLQ-C30 is the most widely used cancer-specific, health-related QoL instrument comprised of 30 individual items arranged as both multi-item scales and individual items. Specifically, these items are divided into 5 functional scales (15 items total), 3 symptom scales (7 items total), 6 individual items, and a GHS/QoL scale composed of 2 items: GHS and QoL. The GHS/QoL score measured here refers to only the composite score calculated for the GHS/QoL scale. Both items on the GHS/QoL scale are scored from 1 (very poor GHS/QoL) to 7 (excellent GHS/QoL) and scores for both items are averaged and a linear transformation applied to standardize the overall GHS/QoL score from 0 to 100, with higher overall scores indicating higher GHS/QoL., Baseline (cycle 1 in neoadjuvant phase) and neoadjuvant week 11|Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score, Change from baseline in GHS/QoL score using the EORTC QLQ-C30 will be determined. The EORTC QLQ-C30 is the most widely used cancer-specific, health-related QoL instrument comprised of 30 individual items arranged as both multi-item scales and individual items. Specifically, these items are divided into 5 functional scales (15 items total), 3 symptom scales (7 items total), 6 individual items, and a GHS/QoL scale composed of 2 items: GHS and QoL. The GHS/QoL score measured here refers to only the composite score calculated for the GHS/QoL scale. Both items on the GHS/QoL scale are scored from 1 (very poor GHS/QoL) to 7 (excellent GHS/QoL) and scores for both items are averaged and a linear transformation applied to standardize the overall GHS/QoL score from 0 to 100, with higher overall scores indicating higher GHS/QoL., Baseline (cycle 1 in neoadjuvant phase) and adjuvant week 10 (up to Study Week 30)|Number of Participants Who Experience an Adverse Event (AE), Up to approximately 71 weeks|Number of Participants Who Experience Perioperative Complications, Perioperative complications are a discrete set of both intraoperative and postoperative complications, potentially contributing to increased length of inpatient care and/or delay of adjuvant therapy. The number of participants experiencing perioperative complications will be assessed., Up to approximately 51 weeks following surgery|Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE), Up to approximately 57 weeks",,Merck Sharp & Dohme LLC,,ALL,"ADULT, OLDER_ADULT",PHASE3,797,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",3475-671|MK-3475-671|183970|2017-001832-21,2018-04-24,2023-07-10,2026-06-29,2018-02-07,2024-09-19,2024-12-03,"Banner MD Anderson Cancer Center ( Site 0028), Gilbert, Arizona, 85234, United States|Western Regional Medical Center, Inc. ( Site 0050), Goodyear, Arizona, 85338, United States|University of Arizona Cancer Center - Dignity Health ( Site 0062), Phoenix, Arizona, 85004, United States|University of Arizona Cancer Center ( Site 0012), Tucson, Arizona, 85724, United States|Pacific Cancer Medical Center, Inc. ( Site 0004), Anaheim, California, 92801, United States|Providence Saint Joseph Medical Center ( Site 0061), Burbank, California, 91505, United States|Pacific Cancer Care ( Site 0035), Monterey, California, 93940, United States|John Wayne Cancer Institute ( Site 0049), Santa Monica, California, 90404, United States|St Joseph Heritage Healthcare ( Site 0040), Santa Rosa, California, 95403, United States|Stanford University, Stanford Cancer Center ( Site 0046), Stanford, California, 94305, United States|Hartford Hospital ( Site 0069), Hartford, Connecticut, 06102, United States|Helen F. Graham Cancer Center & Research Institute ( Site 0015), Newark, Delaware, 19718, United States|Mayo Clinic Jacksonville ( Site 0022), Jacksonville, Florida, 32224, United States|Miami Cancer Institute-Baptist Hospital ( Site 0068), Miami, Florida, 33176, United States|Southeastern Regional Medical Center ( Site 0051), Newnan, Georgia, 30265, United States|Northwest Oncology and Hematology ( Site 0001), Elk Grove Village, Illinois, 60007, United States|Ingalls Memorial Hospital ( Site 0044), Harvey, Illinois, 60426, United States|PPG-Oncology ( Site 0043), Fort Wayne, Indiana, 46845, United States|University of Iowa Hospital and Clinics ( Site 0010), Iowa City, Iowa, 52242, United States|Ashland-Bellefonte Cancer Center ( Site 0021), Ashland, Kentucky, 41101, United States|Harry & Jeanette Weinberg Cancer Institute ( Site 0081), Baltimore, Maryland, 21237, United States|Boston Medical Center ( Site 0057), Boston, Massachusetts, 02118, United States|UMass Memorial Medical Center ( Site 0030), Worcester, Massachusetts, 01655, United States|Henry Ford Health System ( Site 0031), Detroit, Michigan, 48202, United States|Herbert Herman Cancer Center, Sparrow Hospital ( Site 0034), Lansing, Michigan, 48912, United States|Mayo Clinic ( Site 0026), Rochester, Minnesota, 55905, United States|St. Vincent Healthcare Frontier Cancer Center ( Site 0005), Billings, Montana, 59102, United States|University of Nebraska Medical Center ( Site 0047), Omaha, Nebraska, 68198-7680, United States|Memorial Sloan Kettering Cancer Center Basking Ridge ( Site 0074), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0077), Middletown, New Jersey, 07748, United States|MSKCC-Bergen ( Site 0075), Montvale, New Jersey, 07645, United States|St. Peter's Hospital Cancer Care Center ( Site 0039), Albany, New York, 12208, United States|Montefiore Einstein Center ( Site 0016), Bronx, New York, 10461, United States|Memorial Sloan-Kettering Cancer Center at Commack ( Site 0076), Commack, New York, 11725, United States|Memorial Sloan Kettering Cancer Center Westchester ( Site 0079), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center ( Site 0060), New York, New York, 10065, United States|Stony Brook University Medical Center - Cancer Center ( Site 0019), Stony Brook, New York, 11794-9447, United States|Memorial Sloan Kettering Cancer Center - Nassau ( Site 0078), Uniondale, New York, 11553, United States|White Plains Hospital Center for Cancer Care ( Site 0007), White Plains, New York, 10601, United States|Southwestern Regional Medical Center, Inc. ( Site 0054), Tulsa, Oklahoma, 74133, United States|OHSU Center for Health & Healing ( Site 1006), Portland, Oregon, 97239, United States|UPMC Pinnacle Health System - East Location ( Site 0063), Harrisburg, Pennsylvania, 17109, United States|Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0053), Philadelphia, Pennsylvania, 19124, United States|Allegheny General Hospital ( Site 0009), Pittsburgh, Pennsylvania, 15212, United States|UPMC Hillman Cancer Centers ( Site 0041), Pittsburgh, Pennsylvania, 15232, United States|VA Pittsburgh Healthcare System ( Site 0052), Pittsburgh, Pennsylvania, 15240, United States|Saint Francis Cancer Center ( Site 0096), Greenville, South Carolina, 29607, United States|Emily Couric Clinical Cancer Center ( Site 0013), Charlottesville, Virginia, 22903, United States|Inova Schar Cancer Institute ( Site 0032), Fairfax, Virginia, 22031, United States|Virginia Cancer Specialists, PC ( Site 0080), Fairfax, Virginia, 22031, United States|Providence Regional Cancer Partnership ( Site 0065), Everett, Washington, 98201, United States|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0136), Berazategui, Buenos Aires, B1884BBF, Argentina|Hospital Privado de Comunidad. ( Site 0130), Mar del Plata, Buenos Aires, B7602CBM, Argentina|Hospital Universitario Austral ( Site 0127), Pilar, Buenos Aires, B1629ODT, Argentina|Fundacion Favaloro ( Site 0128), Ciudad de Buenos Aires, Caba, C1093AAS, Argentina|Sanatorio Britanico ( Site 0125), Rosario, Santa Fe, S2000CVB, Argentina|Sanatorio Parque ( Site 0135), Rosario, Santa Fe, S2000DSV, Argentina|Hospital Provincial del Centenario ( Site 0131), Rosario, Santa Fe, S2002KDS, Argentina|Hospital Privado Universitario de CÃ³rdoba ( Site 0139), Cordoba, 5016, Argentina|Sanatorio Allende ( Site 0129), Cordoba, X5000JHQ, Argentina|CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0133), San Juan, J5402DIL, Argentina|Orange Health Services ( Site 0624), Orange, New South Wales, 2800, Australia|Westmead Hospital ( Site 0621), Westmead, New South Wales, 2145, Australia|AZ Sint-Maarten ( Site 0226), Mechelen, Antwerpen, 2800, Belgium|Centre Hospitalier Universitaire de LiÃ¨ge - Domaine Universitaire du Sart Tilman ( Site 0223), LiÃ¨ge, Liege, 4000, Belgium|UZ Gent ( Site 0224), Gent, Oost-Vlaanderen, 9000, Belgium|AZ Nikolaas ( Site 0225), Sint-Niklaas, Oost-Vlaanderen, 9100, Belgium|UZ Leuven ( Site 0221), Leuven, Vlaams-Brabant, 3000, Belgium|AZ Delta ( Site 0222), Roeselare, West-Vlaanderen, 8800, Belgium|Centro Regional Integrado de Oncologia ( Site 0160), Fortaleza, Ceara, 60336-232, Brazil|Instituto do Cancer do Ceara ( Site 0152), Fortaleza, Ceara, 60430-230, Brazil|Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul ( Site 0159), Brasilia, Distrito Federal, 70200-730, Brazil|Liga Norte Riograndense Contra o Cancer ( Site 0150), Natal, Rio Grande Do Norte, 59075-740, Brazil|Hospital de Caridade de Ijui ( Site 0153), Ijui, Rio Grande Do Sul, 98700 000, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0146), Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Hospital Nossa Senhora da Conceicao ( Site 0145), Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|YNOVA Pesquisa Clinica ( Site 0823), Florianopolis, Santa Catarina, 88020-210, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0144), Barretos, Sao Paulo, 14784-400, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0149), Rio de Janeiro, 20230-130, Brazil|Hospital Paulistano - Amil Clinical Research ( Site 0822), Sao Paulo, 01321-001, Brazil|Hospital Alemao Oswaldo Cruz ( Site 0158), Sao Paulo, 01327-001, Brazil|Princess Margaret Cancer Centre ( Site 0109), Toronto, Ontario, M5G 2M9, Canada|CIUSSS du Saguenay-Lac-St-Jean ( Site 0101), Chicoutimi, Quebec, G7H 5H6, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0110), Montreal, Quebec, H2X 0C1, Canada|CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0104), Montreal, Quebec, H3T 1M5, Canada|McGill University Health Centre ( Site 0111), Montreal, Quebec, H4A 3J1, Canada|Tianjin Medical University General Hospital ( Site 0806), Tianjin, Anhui, 300052, China|Beijing Cancer Hospital ( Site 0810), Beijing, Beijing, 100010, China|Beijing Cancer Hospital ( Site 0811), Beijing, Beijing, 100010, China|Cancer Hospital Chinese Academy of Medical Sciences ( Site 0801), Beijing, Beijing, 100021, China|Peking University Third Hospital ( Site 0812), Beijing, Beijing, 100191, China|Peking Union Medical College Hospital ( Site 0809), Beijing, Beijing, 100730, China|Sun Yat-Sen University Cancer Center ( Site 0816), Guangzhou, Guangdong, 510060, China|Hunan Cancer Hospital ( Site 0815), Changsha, Hunan, 410013, China|Fudan University Shanghai Cancer Center ( Site 0813), Shanghai, Shanghai, 200032, China|Zhongshan Hospital of Fudan University ( Site 0808), Shanghai, Shanghai, 200032, China|Shanghai Pulmonary Hospital-Thoracic Surgery department ( Site 0817), Shanghai, Shanghai, 200433, China|Tang Du Hospital ( Site 0803), XI An, Shanxi, 710038, China|The First Affiliated Hospital of Zhejiang University ( Site 0804), Hangzhou, Zhejiang, 310003, China|Zhejiang Cancer Hospital.... ( Site 0814), Hangzhou, Zhejiang, 310022, China|Hwa Mei Hospital University of Chinese Academy of Sciences ( Site 0802), Ningbo, Zhejiang, 315010, China|SA Pohja-Eesti Regionaalhaigla ( Site 1100), Tallinn, Harjumaa, 13419, Estonia|Hopital Foch ( Site 0243), Suresnes, Ain, 92150, France|Nouvel Hopital Civil ( Site 0255), Strasbourg, Bas-Rhin, 67091, France|CHU de Toulouse - Hopital Larrey ( Site 0258), Toulouse, Haute-Garonne, 31100, France|Clinique Francois Chenieux ( Site 0246), Limoges, Haute-Vienne, 87039, France|Hospices Civils de Lyon Centre Hospitalier Lyon Sud ( Site 0241), Pierre-Benite, Rhone-Alpes, 69310, France|Centre Hospitalier Metropole Savoie Site de Chambery ( Site 0245), Chambery, Savoie, 73011, France|Centre Hospitalier Annecy Genevois ( Site 0242), Pringy, Savoie, 74374, France|CHU de Rouen ( Site 0252), Rouen, Seine-Maritime, 76031, France|HÃ´pital Avicenne - Service d oncologie medicale ( Site 0249), Bobigny, Seine-Saint-Denis, 93000, France|H.I.A. Sainte-Anne ( Site 0251), Toulon, Var, 83800, France|Institut Curie ( Site 0250), Paris, 75248, France|Klinikum Esslingen GmbH ( Site 0875), Esslingen, Baden-Wurttemberg, 73730, Germany|LKI Lungenfachklinik Immenhausen ( Site 0268), Immenhausen, Hessen, 34376, Germany|Florence Nightingale Krankenhaus ( Site 0874), Duesseldorf, Nordrhein-Westfalen, 40489, Germany|Lungenklinik Hemer ( Site 0269), Hemer, Nordrhein-Westfalen, 58675, Germany|Mathias Spital Rheine ( Site 0261), Rheine, Nordrhein-Westfalen, 48431, Germany|Katholisches Klinikum Koblenz Haus Marienhof ( Site 0873), Koblenz, Rheinland-Pfalz, 56073, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 0273), Dresden, Sachsen, 01307, Germany|Universitaetsklinikum Leipzig AOeR ( Site 0277), Leipzig, Sachsen, 04103, Germany|LungenClinic Grosshansdorf GmbH ( Site 0267), Grosshansdorf, Schleswig-Holstein, 22927, Germany|Universitaetsklinikum Schleswig Holstein ( Site 0871), Kiel, Schleswig-Holstein, 24105, Germany|Zentralklinik Bad Berka GmbH ( Site 0264), Bad Berka, Thuringen, 99437, Germany|SRH Waldklinikum Gera GmbH ( Site 0272), Gera, Thuringen, 07548, Germany|Evangelische Lungenklinik Berlin ( Site 0274), Berlin, 13125, Germany|HELIOS Klinikum Emil von Behring ( Site 0280), Berlin, 14165, Germany|Asklepios Klinikum Hamburg ( Site 0271), Hamburg, 21075, Germany|Cork University Hospital ( Site 0452), Wilton, Cork, Ireland|St James Hospital ( Site 0451), Dublin, D08 K0Y5, Ireland|Mid Western Cancer Centre ( Site 0450), Limerick, V98F858, Ireland|Istituto Nazionale Tumori ( Site 0309), Milano, Abruzzo, 20133, Italy|Azienda Ospedaliera dei Colli V. Monaldi ( Site 0301), Napoli, Campania, 80131, Italy|IRST-Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori ( Site 0300), Meldola, Forli-Cesena, 47014, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0314), Rozzano, Lombardia, 20089, Italy|ASST Grande Ospedale Metropolitano Niguarda-Oncologia Falck ( Site 0315), Milan, Milano, 20162, Italy|Azienda Ospedaliera San Gerardo ( Site 0308), Monza, Monza E Brianza, 20900, Italy|AOU San Luigi Gonzaga di Orbassano ( Site 0313), Orbassano, Torino, 10043, Italy|Azienda Ospedaliera Spedali Civili di Brescia ( Site 0307), Brescia, 25123, Italy|IRCCS Ospedale San Raffaele di Milano ( Site 0303), Milano, 20132, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 0311), Roma, 00152, Italy|Aichi Cancer Center Hospital ( Site 0765), Nagoya, Aichi, 464-8681, Japan|National Cancer Center Hospital East ( Site 0761), Kashiwa, Chiba, 277-8577, Japan|HP of the Univ. of Occupational and Environmental Health, Japan ( Site 0770), Kitakyushu, Fukuoka, 807-8556, Japan|Hyogo Cancer Center ( Site 0764), Akashi, Hyogo, 673-8558, Japan|St. Marianna University School of Medicine Hospital ( Site 0769), Kawasaki, Kanagawa, 216-8511, Japan|Kanagawa Cancer Center ( Site 0763), Yokohama, Kanagawa, 241-8515, Japan|Oita University Hospital ( Site 0766), Yufu, Oita, 879-5593, Japan|Fukushima Medical University Hospital ( Site 0772), Fukushima, 960-1295, Japan|Hiroshima University Hospital ( Site 0762), Hiroshima, 734-8551, Japan|National Cancer Center Hospital ( Site 0767), Tokyo, 104-0045, Japan|Juntendo University Hospital ( Site 0768), Tokyo, 113-8431, Japan|Tokyo Medical University Hospital ( Site 0771), Tokyo, 160-0023, Japan|National Cancer Center ( Site 0702), Gyeonggi-do, Kyonggi-do, 10408, Korea, Republic of|The Catholic University of Korea St. Vincent s Hospital ( Site 0705), Gyeonggi-do, Kyonggi-do, 16247, Korea, Republic of|Asan Medical Center ( Site 0701), Seoul, 05505, Korea, Republic of|Samsung Medical Center ( Site 0704), Seoul, 06351, Korea, Republic of|SMG-SNU Boramae Medical Center ( Site 0707), Seoul, 07071, Korea, Republic of|Pauls Stradins Clinical University Hospital ( Site 0911), Riga, 1002, Latvia|Riga East Clinical University Hospital ( Site 0912), Riga, 1079, Latvia|LSMUL Kauno Klinikos ( Site 0932), Kaunas, 50161, Lithuania|Nacionalinis Vezio Institutas ( Site 0931), Vilnius, 08406, Lithuania|Sarawak General Hospital ( Site 0782), Kuching, Sarawak, 93586, Malaysia|University Malaya Medical Centre ( Site 0781), Kuala Lumpur, 59100, Malaysia|Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 0484), Bystra, Dolnoslaskie, 43-360, Poland|Dolnoslaskie Centrum Onkologii. ( Site 0491), Wroclaw, Dolnoslaskie, 53-413, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0488), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi ( Site 0493), Lodz, Lodzkie, 93-513, Poland|Szpital Specjalistyczny w Prabutach Sp. z o.o. ( Site 0483), Prabuty, Pomorskie, 82-550, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0487), Poznan, Wielkopolskie, 60-569, Poland|S C Pelican Impex SRL ( Site 0506), Oradea, Bihor, 410450, Romania|Centrul Medical Medicover Victoria ( Site 0514), Bucharest, Bucuresti, 010626, Romania|Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0501), Cluj Napoca, Cluj, 400015, Romania|Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0515), Cluj-Napoca, Cluj, 400015, Romania|SC Radiotherapy Center Cluj SRL ( Site 0509), Comuna Floresti, Cluj, 407280, Romania|S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0504), Craiova, Dolj, 200347, Romania|S.C.R.T.C.Radiology Therapeutic Center SRL ( Site 0511), Otopeni, Ilfov, 075100, Romania|S C Oncocenter Oncologie Medicala S R L ( Site 0505), Timisoara, Timis, 300166, Romania|Spitalul Sf. Constantin ( Site 0512), Brasov, 500091, Romania|Euroclinic Hospital Bucharest ( Site 0510), Bucuresti, 014461, Romania|S.C.Focus Lab Plus S.R.L ( Site 0513), Bucuresti, 021389, Romania|Spitalul clinic Judetean de urgenta Constanta ( Site 0508), Constanta, 900591, Romania|Spitalul Judetean de Urgenta .Sf. Ioan cel Nou. ( Site 0503), Suceava, 720237, Romania|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0530), Chelyabinsk, Chelyabinskaya Oblast, 454087, Russian Federation|N.N. Blokhin NMRCO ( Site 0521), Moscow, Moskva, 115478, Russian Federation|National Medical Research Radiology Centre ( Site 0535), Moscow, Moskva, 125284, Russian Federation|Medical Rehabilitation Center ( Site 0534), Moscow, Moskva, 125367, Russian Federation|SBHI Leningrad Regional Clinical Hospital ( Site 0524), Saint Petersburg, Sankt-Peterburg, 194291, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0533), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation|Municipal Clinical Oncology Center ( Site 0523), Saint Petersburg, Sankt-Peterburg, 198255, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0529), Kazan, Tatarstan, Respublika, 420029, Russian Federation|Tomsk Scientific Research Institute of Oncology ( Site 0526), Tomsk, Tomskaya Oblast, 634028, Russian Federation|Wits Clinical Research ( Site 0570), Parktown-Johannesburg, Gauteng, 2193, South Africa|Wilgers Oncology Centre ( Site 0573), Pretoria, Gauteng, 0081, South Africa|The Oncology Centre ( Site 0571), Durban, Kwazulu-Natal, 4001, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 0572), Kraaifontein, Western Cape, 7570, South Africa|Hospital Germans Trias i Pujol. ICO de Badalona ( Site 0381), Badalona, Barcelona, 08916, Spain|Instituto Catalan de Oncologia - ICO ( Site 0388), L Hospitalet De Llobregat, Barcelona, 08908, Spain|Hospital Universitario de Girona Doctor Josep Trueta ( Site 0386), Girona, La Coruna, 17007, Spain|Hospital Universitario Insular de Gran Canaria ( Site 0383), Las Palmas de Gran Canaria, Las Palmas, 35001, Spain|Hospital de la Santa Creu i Sant Pau ( Site 0385), Barcelona, 08025, Spain|Hospital Universitari Vall d Hebron ( Site 0389), Barcelona, 08035, Spain|Hospital General Universitario Gregorio Maranon ( Site 0382), Madrid, 28009, Spain|Hospital Virgen del Rocio ( Site 0387), Sevilla, 41013, Spain|Kaohsiung Chang Gung Memorial Hospital ( Site 0725), Kaohsiung, 83301, Taiwan|China Medical University Hospital ( Site 0724), Taichung, 40447, Taiwan|National Taiwan University Hospital ( Site 0721), Taipei, 10048, Taiwan|Taipei Veterans General Hospital ( Site 0722), Taipei, 112, Taiwan|Tri-Service General Hospital ( Site 0726), Taipei, 114, Taiwan|Chang Gung Medical Foundation.Linkou Branch ( Site 0723), Taoyuan, 333, Taiwan|Cherkassy Regional Oncological Center ( Site 0613), Cherkasy, Cherkaska Oblast, 18009, Ukraine|City Clinical Hosp.4 of DCC ( Site 0607), Dnipro, Dnipropetrovska Oblast, 49102, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 0603), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76018, Ukraine|MI KhRC Kherson Regional Oncology Dispensary ( Site 0614), Kherson, Khersonska Oblast, 73000, Ukraine|PP PPC Acinus Medical and Diagnostic Centre ( Site 0609), Kropyvnytsky, Kirovohradska Oblast, 25006, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 0605), Kyiv, Kyivska Oblast, 03022, Ukraine|Kyiv City Clinical Oncological Center ( Site 0601), Kyiv, Kyivska Oblast, 03115, Ukraine|MI Odessa Regional Oncological Centre ( Site 0608), Odesa, Odeska Oblast, 65055, Ukraine|Zaporizhzhya Regional Clinical Oncology Center ( Site 0606), Zaporizhzhya, Zaporizka Oblast, 69040, Ukraine|Leicester Royal Infirmary ( Site 0447), Leicester, Leicestershire, LE1 5WW, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0456), Wirral, Liverpool, CH63 4JY, United Kingdom|Royal Marsden NHS Foundation Trust ( Site 0458), London, London, City Of, SW3 6JJ, United Kingdom|Royal Marsden Hospital ( Site 0457), Sutton, London, City Of, SM2 5PT, United Kingdom|Nottingham City Hospital Campus ( Site 0441), Nottingham, Nottinghamshire, NG5 1PB, United Kingdom|Heartlands Hospital in Birmingham ( Site 0455), Birmingham, B9 5SS, United Kingdom|Freeman Hospital ( Site 0444), Newcastle upon Tyne, NE7 7DN, United Kingdom|Plymouth Hospitals NHS Trust ( Site 0443), Plymouth, PL6 8DH, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/43/NCT03425643/Prot_SAP_000.pdf"
